Caris Life Sciences Launches AI-Driven Pancreatic Cancer Signature To Guide First-Line Treatment In Pancreatic Ductal Adenocarcinoma

Caris AI Insights are proprietary and only available to Caris Life Sciences customers

IRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch of a novel, proprietary Caris AI Insights™ signature for pancreatic cancer included in the Caris Molecular Tumor Board Report.  The Caris Molecular Tumor Board Report is an innovative tumor profiling report that provides an additional tumor biology resource and is available upon request with no additional tissue sampling required when ordering MI Cancer Seek®.

Caris Life Sciences continues to advance precision oncology by integrating multimodal real-world datasets, available with its proprietary CodeAI™ platform, enabling the creation of Caris AI Insights, an engine that utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and clinical data to generate deeper biological understanding and more actionable insights for clinicians and researchers.

By harnessing AI across its comprehensive real-world datasets, comprised of over 550,000 patients, Caris researchers are building next-generation multimodal models that accelerate biomarker discovery, enhance therapeutic decision-making, and support the development of more personalized cancer treatments.

This signature, designed to support first-line treatment selection for patients with pancreatic ductal adenocarcinoma (PDAC), leverages Caris' WES and WTS to provide biologically informed insights that may help clinicians personalize therapy decisions in one of the deadliest and most treatment-challenging cancers. 

FOLFIRINOX and gemcitabine/nab-paclitaxel (gem/nab-p) are the most commonly used first-line regimens for advanced PDAC, yet limited actionable biomarker guidance exists for therapy selection. As a result, treatment selection often relies on clinical factors rather than tumor biology, exposing patients to potentially unnecessary toxicity with limited benefit.